Obesity

Asthma increased the need for respiratory support in COVID-19 patients, whereas metabolic syndrome raised the risk for severe COVID-19, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

ORLANDO, Fla. — For individuals hospitalized with intracerebral hemorrhage, increased caloric intake that led to an increase in weight was associated with higher odds of survival after 3 months, according to a poster.

The use of glucagon-like peptide-1 receptor agonists exponentially increased in recent years for treating diabetes and obesity, with benefits also observed in other cardiometabolic syndromes.

The explosive popularity of glucagon-like peptide-1 receptor agonists for diabetes and weight loss may have revolutionized obesity management, but their widespread use has also sparked concerns — and ignited a turf war — in the endoscopy suite.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

Patients with asthma who used a glucagon-like peptide 1 receptor agonist for weight loss experienced improved asthma control, according to a poster presented at the European Respiratory Society International Congress.

Intermittent and continuous energy restriction diets both improved cardiometabolic measures and reduced symptoms of depression and disordered eating among adolescents with obesity, according to findings published in JAMA Pediatrics.

A dual GLP-1/GLP-2 receptor agonist did not confer greater body weight reductions for adults with obesity and without diabetes at 12 weeks compared with placebo, according to data from a phase 2a proof-of-concept study.

Obesity prevalence among adults remained high in the United States in 2023, with one in three adults living with obesity in 23 states, according to new CDC data.